Short Interest in Cibus, Inc. (NASDAQ:CBUS) Increases By 19.8%

Cibus, Inc. (NASDAQ:CBUS) was the target of a significant increase in short interest in April. As of April 15th, there was short interest totaling 4,106,540 shares, an increase of 19.8% from the March 31st total of 3,427,664 shares. Currently, 8.6% of the company’s shares are short sold. Based on an average daily volume of 773,409 shares, the days-to-cover ratio is currently 5.3 days.

Cibus Stock Up 3.6%

Cibus stock traded up $0.05 during midday trading on Friday, reaching $1.45. The stock had a trading volume of 324,601 shares, compared to its average volume of 573,995. Cibus has a 12 month low of $1.09 and a 12 month high of $4.19. The company has a market capitalization of $110.71 million, a P/E ratio of -0.49 and a beta of 1.93. The company has a fifty day moving average price of $2.45 and a two-hundred day moving average price of $1.97. The company has a current ratio of 0.72, a quick ratio of 0.72 and a debt-to-equity ratio of 1.37.

Cibus (NASDAQ:CBUS) last issued its earnings results on Tuesday, March 17th. The company reported ($0.42) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.01. Cibus had a negative return on equity of 174.58% and a negative net margin of 3,492.30%.The business had revenue of $1.06 million during the quarter, compared to analyst estimates of $1.64 million. As a group, equities analysts expect that Cibus will post -1.13 EPS for the current fiscal year.

Institutional Trading of Cibus

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CBUS. Bank of America Corp DE increased its holdings in Cibus by 113.4% during the 4th quarter. Bank of America Corp DE now owns 35,536 shares of the company’s stock worth $99,000 after purchasing an additional 18,885 shares in the last quarter. AQR Capital Management LLC bought a new stake in Cibus during the 1st quarter worth approximately $73,000. Qube Research & Technologies Ltd bought a new stake in Cibus during the 2nd quarter worth approximately $39,000. Raymond James Financial Inc. increased its holdings in Cibus by 31.0% during the 2nd quarter. Raymond James Financial Inc. now owns 53,713 shares of the company’s stock worth $74,000 after purchasing an additional 12,722 shares in the last quarter. Finally, Jane Street Group LLC bought a new stake in Cibus during the 2nd quarter worth approximately $207,000. 33.81% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Jefferies Financial Group raised their price objective on shares of Cibus from $1.90 to $3.00 and gave the stock a “hold” rating in a research report on Wednesday, March 25th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cibus in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Cibus has a consensus rating of “Hold” and an average price target of $9.00.

Cibus Company Profile

Cibus, Inc is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company’s platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.

The company’s core business centers on trait development services and licensing partnerships.